Atherosclerosis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Atherosclerosis - Pipeline Review, H2 2015, provides an overview of the Atherosclerosiss therapeutic pipeline.
[USPRwire, Wed Oct 25 2017] This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Atherosclerosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atherosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179104/atherosclerosis-pipeline-review-h2-2015
To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179104/atherosclerosis-pipeline-review-h2-2015
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Atherosclerosis Overview 10
Therapeutics Development 11
Pipeline Products for Atherosclerosis - Overview 11
Pipeline Products for Atherosclerosis - Comparative Analysis 12
Atherosclerosis - Therapeutics under Development by Companies 13
Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 16
Atherosclerosis - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Atherosclerosis - Products under Development by Companies 21
Atherosclerosis - Products under Investigation by Universities/Institutes 24
Atherosclerosis - Companies Involved in Therapeutics Development 26
Ache Laboratorios Farmaceuticos S/A 26
advanceCor GmbH 27
AFFiRiS AG 28
Arisaph Pharmaceuticals, Inc. 29
Artery Therapeutics, Inc. 30
AstraZeneca Plc 31
Athera Biotechnologies AB 32
AtheroNova Inc. 33
Bayer AG 34
Campus Technologies Freiburg GmbH 35
Cardax Pharmaceuticals, Inc. 36
Cerenis Therapeutics Holding SA 37
ChemoCentryx, Inc. 38
CohBar, Inc. 39
Daiichi Sankyo Company, Limited 40
DoNatur GmbH 41
Dybly AG 42
Exicure, Inc. 43
F. Hoffmann-La Roche Ltd. 44
GenKyoTex S.A. 45
Gilead Sciences, Inc. 46
Jenrin Discovery, Inc. 47
Johnson & Johnson 48
KineMed, Inc. 49
Kowa Company, Ltd. 50
La Jolla Pharmaceutical Company 51
Lead Discovery Center GmbH 52
Merck & Co., Inc. 53
MI.TO. Technology S.r.L. 54
Omeros Corporation 55
OPKO Health, Inc. 56
Otsuka Holdings Co., Ltd. 57
Provid Pharmaceuticals, Inc. 58
Resverlogix Corp. 59
The Medicines Company 60
Therapix Biosciences Ltd 61
Tolerys SA 62
Vascular Biogenics Ltd. 63
Vericel Corporation 64
Virocan Therapeutics Private Limited 65
Vitae Pharmaceuticals, Inc. 66
Atherosclerosis - Therapeutics Assessment 67
Assessment by Monotherapy Products 67
Assessment by Combination Products 68
Assessment by Target 69
Assessment by Mechanism of Action 73
Assessment by Route of Administration 76
Assessment by Molecule Type 78
Drug Profiles 80
6860766 - Drug Profile 80
AEM-28 - Drug Profile 81
AG-01 - Drug Profile 82
AHRO-001 - Drug Profile 83
AHRO-002 - Drug Profile 85
AHRO-003 - Drug Profile 86
AM-0010 - Drug Profile 87
AmVidcm-009 - Drug Profile 88
anacetrapib - Drug Profile 89
Annexin A-5 - Drug Profile 91
apabetalone - Drug Profile 93
ARI-1778 - Drug Profile 96
Artpep-2 - Drug Profile 97
ATH-03 - Drug Profile 98
ATH-04 - Drug Profile 99
ATH-05 - Drug Profile 100
ATH-06 - Drug Profile 101
AZ-876 - Drug Profile 102
BAY-606583 - Drug Profile 103
BSN-272 - Drug Profile 104
CCX-771 - Drug Profile 105
CDX-085 - Drug Profile 106
Cell Therapy for Atherosclerosis - Drug Profile 108
Cellular Immunotherapy for Atherosclerosis - Drug Profile 109
CER-209 - Drug Profile 110
CM-7 - Drug Profile 111
COR-2 - Drug Profile 112
D-4F - Drug Profile 113
DIAS-2 - Drug Profile 114
Drug for Atherosclerosis - Drug Profile 115
Drugs to Activate TLR3 for Atherosclerosis - Drug Profile 116
Drugs to Antagonize NMDA Receptor for Atherosclerosis - Drug Profile 117
DYB-186 - Drug Profile 118
EP-80317 - Drug Profile 119
FX-5A - Drug Profile 120
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 121
Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 122
Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile 123
GKT-831 - Drug Profile 124
GYY-4137 - Drug Profile 125
Humanin - Drug Profile 127
INV-88 - Drug Profile 129
ISIS-APOARx - Drug Profile 130
ITP-01 - Drug Profile 131
ixmyelocel-T - Drug Profile 132
JD-2000 Series - Drug Profile 135
JD-5000 Series - Drug Profile 136
JD-6000 Series - Drug Profile 137
K-312 - Drug Profile 138
K-877 - Drug Profile 139
KM-011 - Drug Profile 141
KRP-206 - Drug Profile 142
leucine + niacin - Drug Profile 143
LJPC-6417 - Drug Profile 144
LPC-01 - Drug Profile 145
MCS-18 - Drug Profile 146
MDCO-216 - Drug Profile 148
melittin - Drug Profile 150
Read More http://www.idatainsights.com/reports-landing-page.php?id=179104/atherosclerosis-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.